We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Urine Test Diagnosis Bladder Cancer

By HospiMedica staff writers
Posted on 09 Feb 2007
A new automated test of cells in urine helps detection of bladder cancer.
The fluorescence in-situ hybridization (FISH) identifies chromosome aberrations associated with various diseases. More...
oncoFISH bladder test detects aberrations for chromosomes 3, 7, 9, and 17 in cells found in urine sediment to aid in the initial diagnosis of bladder cancer in patients with hematuria (blood in the urine) and the subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

Ikonisys, Inc. (New Haven, CT,USA), a developer of automated cell-based diagnostic products, announced that the United States Food and Drug Administration (FDA) cleared the company's oncoFISH bladder diagnostic application for marketing in the United States. In conjunction with the company's Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens.

oncoFISH bladder is expected to significantly reduce the time required to process test results while improving the accuracy of bladder cancer diagnosis, and we are prepared for its immediate launch, said Petros Tsipouras, M.D., chairman and CEO of Ikonisys. We believe the Ikoniscope and associated oncoFISH and fastFISH automated diagnostic applications are an economical and dependable solution to subjective sample analysis, protracted turnaround times for test results, and the acute laboratory shortage of trained technical personnel.

Bladder cancer is one of the most common cancers in the United States. More than 61,000 new cases of bladder cancer were diagnosed in 2006 according to the American Cancer Society, and most patients are monitored for recurrent disease.

Ikonisys develops, commercializes, and markets a robotic digital microscopy platform and proprietary diagnostic applications that increase throughput and improve the accuracy of diagnostic screening in the areas of cancer diagnosis and management, prenatal detection of genetic disorders, and fertility. The company has developed two product lines, oncoFISH for cancer diagnostics and monitoring and fastFISH for the prenatal detection of genetic disorders, which are designed to run on the company's robotic digital microscopy platform




Related Links:
Ikonisys Inc
FDA

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.